secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073386
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing
--------------------------------------------------------------------------------

- Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.
- KT-621 (STAT6) Phase 2b in atopic dermatitis (enrollment ongoing) and asthma (dosing started); data expected mid- and late-2027.
- KT-579 (IRF5) Phase 1 healthy volunteer trial dosed; data expected in 2H26.
- Appointed Dr. Neil Graham as Chief Development Officer; he led dupilumab development at Regeneron.
- FY2025 collaboration revenue $39.2M, R&D expense $316.6M, net loss $311.4M (vs. $223.9M in FY2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/0001193125-26-073386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/kymr-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer